CoreFirst Bank & Trust Makes New $28,000 Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

CoreFirst Bank & Trust acquired a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 225 shares of the specialty pharmaceutical company’s stock, valued at approximately $28,000.

Several other large investors also recently made changes to their positions in the business. CIBC Asset Management Inc lifted its stake in Jazz Pharmaceuticals by 5.2% during the fourth quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company’s stock valued at $243,000 after purchasing an additional 97 shares during the last quarter. UMB Bank n.a. lifted its position in shares of Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after acquiring an additional 129 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in shares of Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after acquiring an additional 130 shares in the last quarter. Waterfront Wealth Inc. grew its holdings in shares of Jazz Pharmaceuticals by 1.4% in the 4th quarter. Waterfront Wealth Inc. now owns 9,675 shares of the specialty pharmaceutical company’s stock worth $1,191,000 after acquiring an additional 137 shares during the last quarter. Finally, Ellsworth Advisors LLC raised its position in shares of Jazz Pharmaceuticals by 0.4% during the fourth quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company’s stock worth $4,675,000 after purchasing an additional 149 shares during the period. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $130.88 on Thursday. The firm has a market cap of $7.95 billion, a P/E ratio of 18.43, a PEG ratio of 1.04 and a beta of 0.44. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $148.06. The stock’s 50-day moving average is $132.19 and its two-hundred day moving average is $122.29.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on JAZZ shares. HC Wainwright increased their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a “buy” rating in a research report on Monday, March 10th. Truist Financial raised their target price on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. Piper Sandler restated an “overweight” rating and issued a $176.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Morgan Stanley reaffirmed an “overweight” rating and issued a $183.00 price objective (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 7th. Finally, Needham & Company LLC reissued a “buy” rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 5th. One analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $187.71.

Insider Activity at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the sale, the chief executive officer now directly owns 439,744 shares in the company, valued at approximately $53,785,088.64. This represents a 0.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CAO Patricia Carr sold 4,813 shares of the firm’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.42, for a total value of $695,093.46. Following the transaction, the chief accounting officer now owns 8,237 shares in the company, valued at approximately $1,189,587.54. This trade represents a 36.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,736 shares of company stock valued at $4,022,825. 4.20% of the stock is currently owned by corporate insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.